Rxsight Share Price (NASDAQ: RXST)

$9.05

▲

-0.1

(-1.09%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Rxsight Stock chart to analyse performance

Rxsight stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$8.96
Today's High:$9.21
$9.05
0.99%
Downside
Day's Volatility :2.71%
Upside
1.74%
52 Weeks Low:$6.32
52 Weeks High:$57.53
$9.05
30.17%
Downside
52 Weeks Volatility :89.01%
Upside
84.27%

Rxsight Stock Returns

Period	Rxsight Inc	Index (Russel 2000)
3 Months	-41.79%	0.0%
6 Months	-66.43%	0.0%
1 Year	-83.0%	0.0%
3 Years	-29.32%	-4.1%

Rxsight Inc Key Stats

Check Rxsight key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$9.15
Open	$9.1
Today's High	$9.21
Today's Low	$8.96
Market Capitalization	$374.4M
Today's Volume	$1.2M
52 Week High	$57.53
52 Week Low	$6.32
Revenue TTM	$147.1M
EBITDA	$-39.3M
Earnings Per Share (EPS)	$-0.8
Profit Margin	-21.93%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-11.66%

Stock Returns calculator for Rxsight Stock including INR - Dollar returns

The Rxsight stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Rxsight investment value today

Current value as on today

₹22,299

Returns

₹77,701

(-77.7%)

Returns from Rxsight Stock

₹82,986 (-82.99%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Rxsight Stock

-83%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Rxsight Stock from India on INDmoney has decreased by -83% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Rxsight Inc

Name
Holdings %
Name
Holdings %
RA Capital Management, LLC
9.05%
BlackRock Inc
7.52%
Vanguard Group Inc
5.57%
Artisan Partners Limited Partnership
5.51%
Bank of America Corp
5.34%
D. E. Shaw & Co LP
3.23%

Analyst Recommendation on Rxsight Stock

Rating

Trend

Buy

92%Buy

7%Hold

0%Sell

Based on 14 Wall street analysts offering stock ratings for Rxsight(by analysts ranked 0 to 5 stars)

Rxsight Share Price Target

What analysts predicted

Downside of 1.78%

Target:

$8.89

Current:

$9.05

Rxsight share price target is $8.89, a slight Downside of 1.78% compared to current price of $9.05 as per analysts' prediction.

Rxsight Stock Insights

Price Movement
In the last 3 months, RXST stock has moved down by -40.9%
Decreasing Revenue
Revenue is down for the last 4 quarters, 45.40M → 33.63M (in $), with an average decrease of 9.5% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, -5.93M → -11.78M (in $), with an average decrease of 40.9% per quarter
RXST vs BSX (1 yr)
In the last 1 year, Boston Scientific Corp. has given 29.0% return, outperforming this stock by 113.0%
RXST vs BSX (3 yr)
In the last 3 years, Boston Scientific Corp. has given 161.7% return, outperforming this stock by 189.4%
Price to Sales
ForRXST every $1 of sales, investors are willing to pay $2.5, whereas for Boston Scientific Corp., the investors are paying $8.4 for every $1 of sales.

Rxsight Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$2.2M	-
Net Income	$126.2M	-
Net Profit Margin	5.6K%	-

	FY20	Y/Y Change
Revenue	$14.7M	↑ 554.98%
Net Income	$27.6M	↓ 78.15%
Net Profit Margin	187.87%	↓ 5444.44%

	FY21	Y/Y Change
Revenue	$22.6M	↑ 53.92%
Net Income	$-48.7M	↓ 276.57%
Net Profit Margin	-215.5%	↓ 403.37%

	FY22	Y/Y Change
Revenue	$49.0M	↑ 116.9%
Net Income	$-66.8M	↑ 37.11%
Net Profit Margin	-136.22%	↑ 79.28%

	FY23	Y/Y Change
Revenue	$89.1M	↑ 81.77%
Net Income	$-48.6M	↓ 27.19%
Net Profit Margin	-54.57%	↑ 81.65%

	FY24	Y/Y Change
Revenue	$139.9M	↑ 57.09%
Net Income	$-27.5M	↓ 43.52%
Net Profit Margin	-19.62%	↑ 34.95%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$29.5M	↑ 3.26%
Net Income	$-9.1M	↓ 0.84%
Net Profit Margin	-30.83%	↑ 1.28%

	Q2 FY24	Q/Q Change
Revenue	$34.9M	↑ 18.21%
Net Income	$-6.1M	↓ 33.2%
Net Profit Margin	-17.42%	↑ 13.41%

	Q3 FY24	Q/Q Change
Revenue	$45.4M	↑ 30.16%
Net Income	$-6.3M	↑ 4.26%
Net Profit Margin	-13.96%	↑ 3.46%

	Q4 FY24	Q/Q Change
Revenue	$40.2M	↓ 11.44%
Net Income	$-5.9M	↓ 6.31%
Net Profit Margin	-14.77%	↓ 0.81%

	Q1 FY25	Q/Q Change
Revenue	$37.9M	↓ 5.77%
Net Income	$-8.2M	↑ 37.93%
Net Profit Margin	-21.61%	↓ 6.84%

	Q2 FY25	Q/Q Change
Revenue	$33.6M	↓ 11.24%
Net Income	$-11.8M	↑ 43.91%
Net Profit Margin	-35.04%	↓ 13.43%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$-1.8M	-

	FY20	Y/Y Change
Profit	$1.7M	↓ 193.73%

	FY21	Y/Y Change
Profit	$4.5M	↑ 164.93%

	FY22	Y/Y Change
Profit	$21.3M	↑ 372.17%

	FY23	Y/Y Change
Profit	$53.8M	↑ 152.09%

	FY24	Y/Y Change
Profit	$98.9M	↑ 84.03%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$20.7M	↑ 17.17%

	Q2 FY24	Q/Q Change
Profit	$24.3M	↑ 17.23%

	Q3 FY24	Q/Q Change
Profit	$25.2M	↑ 4.0%

	Q4 FY24	Q/Q Change
Profit	$28.8M	↑ 14.15%

	Q1 FY25	Q/Q Change
Profit	$28.3M	↓ 1.59%

	Q2 FY25	Q/Q Change
Profit	$25.2M	↓ 11.08%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-40.6M	-
Investing Cash Flow	$-5.9M	-
Financing Cash Flow	$1.3M	-

	FY20	Y/Y Change
Operating Cash Flow	$-35.2M	↓ 13.33%
Investing Cash Flow	$15.6M	↓ 365.6%
Financing Cash Flow	$25.2M	↑ 1797.52%

	FY21	Y/Y Change
Operating Cash Flow	$-44.7M	↑ 27.0%
Investing Cash Flow	$-81.9M	↓ 625.35%
Financing Cash Flow	$137.3M	↑ 444.21%

	FY22	Y/Y Change
Operating Cash Flow	$-58.9M	↑ 31.63%
Investing Cash Flow	$40.0M	↓ 148.77%
Financing Cash Flow	$6.3M	↓ 95.39%

	FY23	Y/Y Change
Operating Cash Flow	$-41.6M	↓ 29.32%
Investing Cash Flow	$-22.1M	↓ 155.39%
Financing Cash Flow	$61.5M	↑ 871.64%

	FY24	Y/Y Change
Operating Cash Flow	$-16.9M	↓ 59.26%
Investing Cash Flow	$-99.3M	↑ 348.78%
Financing Cash Flow	$123.3M	↑ 100.44%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-9.3M	↑ 12.14%
Investing Cash Flow	$24.3M	↑ 431.63%
Financing Cash Flow	$8.0M	↑ 124.37%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-4.1M	↓ 55.88%
Investing Cash Flow	$-115.6M	↓ 576.42%
Financing Cash Flow	$111.6M	↑ 1295.81%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$650.0K	↓ 115.83%
Investing Cash Flow	$-9.3M	↓ 91.99%
Financing Cash Flow	$878.0K	↓ 99.21%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-4.3M	↓ 755.38%
Investing Cash Flow	$1.3M	↓ 114.25%
Financing Cash Flow	$3.0M	↑ 238.95%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-8.8M	↑ 107.32%
Investing Cash Flow	$20.9M	↑ 1479.92%
Financing Cash Flow	$-735.0K	↓ 124.7%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-4.4M	↓ 50.45%
Investing Cash Flow	$14.7M	↓ 29.74%
Financing Cash Flow	$2.1M	↓ 380.95%

Rxsight Technicals Summary

Sell

Neutral

Buy

Rxsight is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Rxsight Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Rxsight Inc	15.9%	-66.43%	-83.0%	-29.32%	-43.5%
Medtronic Plc	3.87%	-1.59%	4.32%	4.82%	-13.69%
Edwards Lifesciences Corp.	2.55%	13.95%	18.33%	-9.73%	-5.31%
Boston Scientific Corp.	0.09%	0.6%	30.02%	157.38%	154.4%
Stryker Corporation	3.63%	-0.85%	8.87%	89.43%	97.71%
Abbott Laboratories	4.24%	-5.37%	15.72%	26.56%	24.53%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Rxsight Inc	NA	NA	NA	-0.58	-0.12	-0.09	NA	6.8
Medtronic Plc	25.4	25.4	2.14	5.46	0.1	0.05	0.03	37.36
Edwards Lifesciences Corp.	34.03	34.03	4.85	2.5	0.16	0.08	NA	17.94
Boston Scientific Corp.	62.95	62.95	1.84	2.98	0.12	0.05	NA	15.14
Stryker Corporation	51.54	51.54	2.24	13.49	0.14	0.08	0.01	55.43
Abbott Laboratories	16.64	16.64	4.17	5.14	0.31	0.07	0.02	29.05

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Rxsight Inc	Buy	$374.4M	-43.5%	NA	-21.93%
Medtronic Plc	Buy	$118.0B	-13.69%	25.4	13.63%
Edwards Lifesciences Corp.	Buy	$47.8B	-5.31%	34.03	72.96%
Boston Scientific Corp.	Buy	$156.7B	154.4%	62.95	13.55%
Stryker Corporation	Buy	$149.0B	97.71%	51.54	12.25%
Abbott Laboratories	Buy	$230.9B	24.53%	16.64	32.43%

Rxsight Dividend announcements

Rxsight Earnings
Rxsight’s price-to-earnings ratio stands at None

About Rxsight Inc

RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Organization	Rxsight
Employees	498
CEO	Dr. Ronald M. Kurtz M.D.
Industry	Miscellaneous

Key Management of Rxsight Inc

Name	Title
Dr. Ronald M. Kurtz M.D.	Co-President, CEO & Director
Mr. Eric J. Weinberg	Co-President & Chief Commercial Officer
Ms. Shelley B. Thunen	Co-President & CFO
Dr. Ilya Goldshleger Ph.D.	Co-President & COO
Mr. Glebb Popov	Vice President of Finance & Accounting
Mr. Matt Haller Ph.D.	Chief Technology Officer
Mr. Oliver Moravcevic	Vice President of Investor Relations
Mr. Steve Everly	Senior VP of Sales of North America
Mr. Roy Freeman	Senior VP of Marketing & Professional Relations
Ms. Caroline Vaughn	Vice President of Human Resources

Important FAQs about investing in RXST Stock from India :

What is Rxsight share price today?

Rxsight share price today is $9.05 as on August 30, 2025 at 1:29 am IST at the close of the market. Rxsight share today touched a day high of $9.21 and a low of $8.96.

What is the 52 week high and 52 week low for Rxsight share?

Rxsight share touched a 52 week high of $57.53 and a 52 week low of $6.32. Rxsight stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $9.05, lower by 84.27% versus the 52 week high.

How to invest in Rxsight Stock (RXST) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Rxsight on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Rxsight Shares that will get you 0.1657 shares as per Rxsight share price of $9.05 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Rxsight Stock (RXST) from India?

Indian investors can start investing in Rxsight (RXST) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Rxsight stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Rxsight share’s latest price of $9.05 as on August 30, 2025 at 1:29 am IST, you will get 1.1050 shares of Rxsight. Learn more about fractional shares .

What are the returns that Rxsight has given to Indian investors in the last 5 years?

Rxsight stock has given -43.5% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?